Oppenheimer & Co. Inc. Increases Holdings in VanEck Pharmaceutical ETF (NASDAQ:PPH)

Oppenheimer & Co. Inc. increased its position in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 7.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 13,445 shares of the company’s stock after acquiring an additional 990 shares during the quarter. Oppenheimer & Co. Inc. owned about 0.18% of VanEck Pharmaceutical ETF worth $1,278,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Optimum Investment Advisors purchased a new position in VanEck Pharmaceutical ETF in the 2nd quarter worth approximately $27,000. GPS Wealth Strategies Group LLC bought a new stake in VanEck Pharmaceutical ETF in the second quarter worth $42,000. CWM LLC bought a new stake in VanEck Pharmaceutical ETF in the second quarter worth $55,000. International Assets Investment Management LLC bought a new position in shares of VanEck Pharmaceutical ETF during the second quarter valued at $86,000. Finally, Comerica Bank lifted its holdings in shares of VanEck Pharmaceutical ETF by 39.4% during the first quarter. Comerica Bank now owns 1,337 shares of the company’s stock valued at $121,000 after purchasing an additional 378 shares in the last quarter.

VanEck Pharmaceutical ETF Price Performance

Shares of NASDAQ:PPH opened at $86.61 on Tuesday. The company has a market cap of $640.05 million, a P/E ratio of 21.04 and a beta of 0.72. VanEck Pharmaceutical ETF has a 1 year low of $77.04 and a 1 year high of $99.51. The stock’s fifty day moving average price is $93.47 and its 200-day moving average price is $93.05.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.